中文摘要：

目的 研究维生素D在慢性丙型肝炎（CHC）患者接受聚乙二醇干扰素α-2b（Peg-IFNα-2b）联合利巴韦林（RBV）抗病毒治疗中的作用。方法 本研究为前瞻性随机对照试验,共纳入52例CHC初治患者,随机分为维生素D补充治疗组（A组）、对照组（B组）,A组26例患者口服补充维生素D 800 IU/d至Peg-IFNα-2b/RBV抗病毒治疗结束,B组26例患者仅接受Peg-IFNα-2b/RBV抗病毒治疗。检测患者治疗前、治疗4周、12周、24周、48周时HCV RNA水平等指标。结果 治疗24周、48周时维生素D补充治疗组病毒学应答率均显著高于对照组（95.8%vs 69.6%,95.8%vs 73.9%,P均〈0.05）,但两组早期病毒学应答（EVR）无统计学差异（91.7%vs 69.6%,P〉0.05）。两组不良事件发生率并无差异（73.1%vs 80.8%,P〉0.05）。结论 补充维生素D能提高CHC患者Peg-IFNα-2b/RBV抗病毒疗效。

英文摘要：

Objective To study the effect of vitamin D on the antiviral therapy of pegylated interferon α-2b（Peg-IFNα- 2b） combined with ribavirin（RBV） in the patients with chronic hepatitis C（CHC）. Methods The study was a prospective, randomized and controlled trial. A total of 52 patients with CHC were enrolled in this study. They were randomly divided into vitamin D supplementation group （group A）, control group （group B）. Group A of 26 patients was orally given vita- min D 800 IU/d until the end of antiviral therapy of Peg-IFNα-2b/RBV, while group B of 26 patients was only given antiviral therapy of Peg-IFNα-2b/RBV. The levels of HCV RNA were measured before the treatment and 4 weeks, 12 weeks, 24 weeks and 48 weeks after the treatment. Results The virological response rate in the vitamin D supplementa- tion group at 24 weeks and 48 weeks was significantly higher than that in the control group （95.8% vs 69.6%, 95.8% vs 73.9%, P all 〈0.05）. However, there was no significant difference in early virological response （EVR） between the two groups（91.7% vs 69.6%, P〉0.05）. There was no difference in the incidence rate of adverse events between the two groups （73.1% vs 80.8%, P〉0.05）. Conclusion Vitamin D supplementation can improve the antiviral efficacy of Peg-IFNα-2b/ RBV in CHC patients.